Efforts to develop neuroprotective therapy for Parkinson disease (PD) are focusing on the
early stages of disease, which offer the best opportunity to intervene. Early PD can be …

The etiology of Parkinson's disease (PD) is not well understood but likely to involve both
genetic and environmental factors. Incidence and prevalence estimates vary to a large …

Objective Quantification of gait with wearable technology is promising; recent cross‐
sectional studies showed that gait characteristics are potential prodromal markers for …

Olfactory dysfunction is among the earliest nonmotor features of Parkinson disease (PD).
Such dysfunction is present in approximately 90% of early-stage PD cases and can precede …

Oxidative stress contributes to the cascade leading to dopamine cell degeneration in
Parkinson's disease (PD). However, oxidative stress is intimately linked to other components …

Although most cases of Alzheimer's and Parkinson's disease are sporadic, some cases are
clearly familial. This review, part of the Genomic Medicine series, examines the genetics of …

Parkinson's disease (PD) is currently clinically defined by a set of cardinal motor features
centred on the presence of bradykinesia and at least one additional motor symptom out of …

Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder associated with
akinesia, tremor and rigidity. While the characteristic Lewy body pathology targets …

Parkinson's disease (PD) is a neurodegenerative disorder that affects millions of people
worldwide. Two hallmarks of PD are the accumulation of alpha‐synuclein and the loss of …

Parkinson's disease is a widespread degenerative illness affecting the human central,
peripheral, and enteric nervous systems. The underlying pathological process progresses …